These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14956388)

  • 1. [Intravenous iron therapy].
    Med Contemp; 1952 May; 70(5):299-301. PubMed ID: 14956388
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous iron therapy.
    VARIAVA NS
    Antiseptic; 1952 Mar; 49(3):210-7. PubMed ID: 14934073
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical experiences with intravenous iron therapy].
    SELIGER H
    Ther Ggw; 1952 Feb; 91(2):55-7. PubMed ID: 14922346
    [No Abstract]   [Full Text] [Related]  

  • 4. [Intravenous iron].
    DUFRESNE RR
    Union Med Can; 1952 Jun; 81(6):697-8. PubMed ID: 13005802
    [No Abstract]   [Full Text] [Related]  

  • 5. [Tolerance of intravenous iron application].
    GOLDECK H; REMY D; MEYER F
    Arztl Wochensch; 1952 May; 7(21):489-90. PubMed ID: 14952397
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravenous iron treatment in general practice.
    ISAACS B
    Practitioner; 1952 Jul; 168(1009):67-71. PubMed ID: 14948760
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravenous iron therapy in pediatrics.
    HAGBERG B
    Acta Paediatr (Stockh); 1951 Nov; 40(6):519-40. PubMed ID: 14933007
    [No Abstract]   [Full Text] [Related]  

  • 8. [The passage of intravenously injected iron from the blood stream].
    OVERKAMP H
    Z Gesamte Exp Med; 1952; 120(1):86-95. PubMed ID: 13057308
    [No Abstract]   [Full Text] [Related]  

  • 9. [The behavior of intravenously administered iron in the organism].
    LINTZEL W
    Arztl Forsch; 1953 Mar; 7(3):I/134-6. PubMed ID: 13065190
    [No Abstract]   [Full Text] [Related]  

  • 10. [Intravenous iron therapy with ferrum injectabile Vitis].
    PRIBILLA W
    Medizinische; 1952 Jun; 2():53-6. PubMed ID: 14940483
    [No Abstract]   [Full Text] [Related]  

  • 11. Iron in hematology: Danger with IV iron: Real or perceived?
    Auerbach M
    Am J Hematol; 2014 Jun; 89(6):664. PubMed ID: 24639085
    [No Abstract]   [Full Text] [Related]  

  • 12. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Balancing Benefits and Safety with Intravenous Iron Treatment.
    Alan Brookhart M; Li X; Kshirsagar AV
    Semin Dial; 2017 Jan; 30(1):25-27. PubMed ID: 27766683
    [No Abstract]   [Full Text] [Related]  

  • 13. [A new and very effective type of peroral iron therapy with capsules].
    GECK K
    Ther Ggw; 1952 Nov; 91(11):414-6. PubMed ID: 13029081
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravenous iron therapy in end-stage renal disease.
    Brewster UC
    Semin Dial; 2006; 19(4):285-90. PubMed ID: 16893405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: The Benefits of Intravenous Iron.
    Wish JB
    Semin Dial; 2017 Jan; 30(1):20-22. PubMed ID: 27679413
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravenous administration of iron gluconate during haemodialysis.
    Calvar C; Mata D; Alonso C; Ramos B; Lopez de Novales E
    Nephrol Dial Transplant; 1997 Mar; 12(3):574-5. PubMed ID: 9075144
    [No Abstract]   [Full Text] [Related]  

  • 17. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Emerging Evidence on the Safety of Intravenous Iron in Chronic Kidney Disease.
    Agarwal R
    Semin Dial; 2017 Jan; 30(1):22-25. PubMed ID: 27678472
    [No Abstract]   [Full Text] [Related]  

  • 18. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: The Role for Newly Approved Iron Treatments.
    Fishbane S
    Semin Dial; 2017 Jan; 30(1):27-29. PubMed ID: 27687015
    [No Abstract]   [Full Text] [Related]  

  • 19. New intravenous iron replacement therapies.
    Auerbach M
    Clin Adv Hematol Oncol; 2010 Oct; 8(10):688-9. PubMed ID: 21317865
    [No Abstract]   [Full Text] [Related]  

  • 20. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal Disease.
    Besarab A; Szczech L
    Semin Dial; 2017 Jan; 30(1):29-31. PubMed ID: 27699882
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.